



## Going global: Exploring the best opportunities for value investors



From the Field  
November 2023

### Key Insights

- Having a global opportunity set that offers both cyclical and defensive attributes is attractive for investors seeking balance in their portfolios.
- Energy, health care, and technology are all areas where we are currently finding opportunity.
- With stock prices oscillating more than their underlying fundamentals, value investors can take advantage of mispricings and investors' short-term horizons.



**Sebastien Mallet**  
Portfolio Manager,  
Global Value Equity Strategy

Value investing has a long history of delivering above-market returns, but since the global financial crisis, value-oriented strategies have struggled as subdued economic growth, very low inflation, and ultralow levels of interest rates have hindered performance. This period has been highly unusual, but with the return of inflation and central banks implementing one of the fastest rate-hiking cycles in history, we have seen a material evolution in the market environment back to a more normal one. The field is now much more even, offering increased opportunities for value investors.

### Return to normalized world provides a more positive backdrop for value

While there are parts of the value universe that are economically sensitive, such as banks and “highly cyclical” industrials, there is also a strong balance of defensive areas, such as health care, and companies that have strong pricing power, especially in traditional industries such as utilities and consumer staples where higher inflation has clear benefits.

Meanwhile, with supply chains being restored and the effects of deglobalization and onshoring accelerating, we are expecting higher levels of capital expenditure going forward. Higher inflation will also mean corporates



The field is now much more even, offering increased opportunities for value investors.

“ A combination of higher capital expenditure and fiscal spending is likely to prove beneficial for value-oriented areas of the market.

and governments will be less likely to postpone investments due to the potential for higher costs in the future.

This should also be accelerated by the desire to meet net zero targets. However, the push for cleaner energy and decarbonization is not only limited to energy companies. Across industries, we are witnessing greater investment as companies endeavor to meet ambitious green targets. Further, governments may be more willing to engage in higher levels of fiscal spending to beat inflation, but also to address future economic shocks

and fulfill a social agenda, as they have seen how effective such spending has been in the recent past. A combination of higher capital expenditure and fiscal spending is likely to prove beneficial for value-oriented areas of the market.

Identifying opportunities from a global value perspective

Having a global opportunity set that offers both cyclical and defensive attributes is attractive for investors seeking balance in their portfolios. We have identified three key areas where we see exciting opportunities going forward.

Energy dynamics—Rising energy prices and the focus on energy independence and transition

Energy prices are rising as geopolitical concerns increase, inventories are low, and the cost of capital has expanded. Oil prices have risen solidly since the summer trough as geopolitics have amplified the desire for energy security and independence, while rig counts in the U.S. have fallen. The war in Ukraine and the recent events in Gaza and Israel

have focused investor attention on energy supplies. Further, a lack of investment, especially in oil and natural gas extraction, has also caused prices to rise. The cost to pull energy from the ground has risen steadily due to the higher cost of financing, hiring, and transportation. There are also some indications that the long-term trend of improving productivity is reversing. Meanwhile, winter is coming. Europe escaped 2022 with a mild winter, but there is no guarantee of that happening again this winter. All these factors support higher energy prices, and with it, potentially improving returns for energy companies.

Health care—Innovation, new products, and finding areas of controversy

The coronavirus pandemic brought into sharp focus the critical importance of global health care investment, innovation, and access. The pandemic prompted governments to increase capital flows across a range of industries to strengthen the resilience of global health care systems, and we anticipate that this will support a period of innovation, consolidation, and optimization.

Three themes to watch in the value space



Energy dynamics

Rising energy prices improve prospects for energy firms



Health care

Strong capital investment and drug development



Information technology

Volatility widens the opportunity set for value investors

Health care is an area that is consistently growing and developing. The sector has also displayed resilience during periods of market uncertainty, as the general inelasticity of demand for health care products and services has typically helped in times of weak sentiment. The bigger headwinds arise from factors such as patent expirations of blockbuster drugs, the success of development pipelines, and political risk relating to drug pricing, especially in the U.S. However, free cash flow generation remains strong in the sector, and we are encouraged by the drug pipeline, especially in areas of diabetes, Alzheimer's disease, and cardiovascular conditions.

Beyond the general defensive profile, there can also be controversies that present investment opportunities. More recently, doubts around accessing financing for biologics and life science companies in a regime of sharp monetary tightening have weighed on the performance of equipment suppliers.

We also need to assess the impact of new GLP-1<sup>1</sup> drugs that could dramatically enhance weight loss. This has a potential knock-on effect on medical care companies, as well as on food and drink companies. Many investors are also still concerned by the "coronavirus unwind" in different segments of the industry. Finding pockets of value in such environments, however, has shown to be successful over the longer term.

## Technology—Expanding the opportunity set

Many value managers tend to allocate minimal resources to finding opportunities within the information technology sector due to the high valuations and long duration that industries within the space can present. But opportunities can still be found, especially when sentiment turns against a sector and uncertainty is high. This is especially true in "cyclical tech," currently, which includes semiconductor and semiconductor equipment companies. In particular, we have made a number of investments in memory chip companies.

The cyclical nature of the tech sector arises from the nature of customer demand, investment and inventory patterns, and other competitive behaviors that can cause sharp swings in industry returns and profitability. In the midst of this volatility, opportunities can arise as investors try to avoid the downturn as the cycle deteriorates and the market overly extrapolates trends into the future. The short-term fear of the unknown can therefore create opportunity to unearth potential new investment candidates as the near-term reduction in market value is balanced with the potential intrinsic value of the company.

 Value investing has performed well in a range of different economic environments.

### Importance of finding balance within a portfolio

Value investing has performed well in a range of different economic environments. While a number of factors have made investing more difficult in recent years, the classic value investing model has not fundamentally changed. Investing in companies that trade below their intrinsic value continues to prove a successful strategy. Meanwhile, short-term disruption, controversy, or setbacks in the market continue to cause equity mispricing.

With stock prices oscillating more than their underlying fundamentals, there are opportunities to take advantage of these mispricings and investors' short-term horizons. In today's market, with high economic and geopolitical uncertainty, it is important to maintain a well diversified portfolio across factor, style, and economic exposures.

<sup>1</sup> GLP-1: Glucagon-like peptide-1 receptor agonists are a class of drugs that reduce blood sugar and energy intake by activating the GLP-1 receptor.

**T. Rowe Price cautions that economic estimates and forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Actual outcomes could differ materially from those anticipated in estimates and forward-looking statements, and future results could differ materially from historical performance. The information presented herein is shown for illustrative, informational purposes only. Any historical data used as a basis for analysis are based on information gathered by T. Rowe Price and from third-party sources and have not been verified. Forecasts are based on subjective estimates about market environments that may never occur. Any forward-looking statements speak only as of the date they are made. T. Rowe Price assumes no duty to, and does not undertake to, update forward-looking statements.**

## INVEST WITH CONFIDENCE™

T. Rowe Price identifies and actively invests in opportunities to help people thrive in an evolving world, bringing our dynamic perspective and meaningful partnership to clients so they can feel more confident.

---

### Important Information

**This material is being furnished for general informational and/or marketing purposes only.** The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice, nor is it intended to serve as the primary basis for an investment decision. Prospective investors are recommended to seek independent legal, financial and tax advice before making any investment decision. T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services. **Past performance is not a reliable indicator of future performance.** The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested.

The material does not constitute a distribution, an offer, an invitation, a personal or general recommendation or solicitation to sell or buy any securities in any jurisdiction or to conduct any particular investment activity. The material has not been reviewed by any regulatory authority in any jurisdiction.

Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources' accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date written and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.

The material is not intended for use by persons in jurisdictions which prohibit or restrict the distribution of the material and in certain countries the material is provided upon specific request. It is not intended for distribution to retail investors in any jurisdiction.

**DISCLOSURE CONTINUES ON THE FOLLOWING PAGE.**

---

## Important Information (cont.)

**Australia**—Issued by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 28, Governor Phillip Tower, 1 Farrer Place, Sydney NSW 2000, Australia. For Wholesale Clients only.

**Brunei**—This material can only be delivered to certain specific institutional investors for informational purpose only. Any strategy and/or any products associated with the strategy discussed herein has not been authorised for distribution in Brunei. No distribution of this material to any member of the public in Brunei is permitted.

**Canada**—Issued in Canada by T. Rowe Price (Canada), Inc. T. Rowe Price (Canada), Inc.'s investment management services are only available to Accredited Investors as defined under National Instrument 45-106. T. Rowe Price (Canada), Inc. enters into written delegation agreements with affiliates to provide investment management services.

**Colombia, Chile, Mexico, Perú, Uruguay**—This material is prepared by T. Rowe Price International Ltd - Warwick Court, 5 Paternoster Square, London, EC4M 7DX which is authorised and regulated by the UK Financial Conduct Authority - and issued and distributed by locally authorized distributors only. For professional investors only.

**DIFC**—Issued in the Dubai International Financial Centre by T. Rowe Price International Ltd which is regulated by the Dubai Financial Services Authority as a Representative Office. For Professional Clients only.

**EEA**—Unless indicated otherwise this material is issued and approved by T. Rowe Price (Luxembourg) Management S.à r.l. 35 Boulevard du Prince Henri L-1724 Luxembourg which is authorised and regulated by the Luxembourg Commission de Surveillance du Secteur Financier. For Professional Clients only.

**Hong Kong**—Issued in Hong Kong by T. Rowe Price Hong Kong Limited, 6/F, Chater House, 8 Connaught Road Central, Hong Kong. T. Rowe Price Hong Kong Limited is licensed and regulated by the Securities & Futures Commission. For Professional Investors only.

**Indonesia**—This material is intended to be used only by the designated recipient to whom T. Rowe Price delivered; it is for institutional use only. Under no circumstances should the material, in whole or in part, be copied, redistributed or shared, in any medium, without prior written consent from T. Rowe Price. No distribution of this material to members of the public in any jurisdiction is permitted.

**Korea**—This material is intended only to Qualified Professional Investors. Not for further distribution.

**Mainland China**—This material is provided to qualified investors only. No invitation to offer, or offer for, or sale of, the shares will be made in the mainland of the People's Republic of China ("Mainland China", not including the Hong Kong or Macau Special Administrative Regions or Taiwan) or by any means that would be deemed public under the laws of the Mainland China. The information relating to the strategy contained in this material has not been submitted to or approved by the China Securities Regulatory Commission or any other relevant governmental authority in the Mainland China. The strategy and/or any product associated with the strategy may only be offered or sold to investors in the Mainland China that are expressly authorized under the laws and regulations of the Mainland China to buy and sell securities denominated in a currency other than the Renminbi (or RMB), which is the official currency of the Mainland China. Potential investors who are resident in the Mainland China are responsible for obtaining the required approvals from all relevant government authorities in the Mainland China, including, but not limited to, the State Administration of Foreign Exchange, before purchasing the shares. This document further does not constitute any securities or investment advice to citizens of the Mainland China, or nationals with permanent residence in the Mainland China, or to any corporation, partnership, or other entity incorporated or established in the Mainland China.

**Malaysia**—This material can only be delivered to specific institutional investor. This material is solely for institutional use and for informational purposes only. This material does not provide investment advice or an offering to make, or an inducement or attempted inducement of any person to enter into or to offer to enter into, an agreement for or with a view to acquiring, disposing of, subscribing for or underwriting securities. Nothing in this material shall be considered a making available of, solicitation to buy, an offering for subscription or purchase or an invitation to subscribe for or purchase any securities, or any other product or service, to any person in any jurisdiction where such offer, solicitation, purchase or sale would be unlawful under the laws of Malaysia.

**New Zealand**—Issued by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 28, Governor Phillip Tower, 1 Farrer Place, Sydney NSW 2000, Australia. No Interests are offered to the public. Accordingly, the Interests may not, directly or indirectly, be offered, sold or delivered in New Zealand, nor may any offering document or advertisement in relation to any offer of the Interests be distributed in New Zealand, other than in circumstances where there is no contravention of the Financial Markets Conduct Act 2013.

**Philippines**—ANY STRATEGY AND/ OR ANY SECURITIES ASSOCIATED WITH THE STRATEGY BEING DISCUSSED HEREIN HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES REGULATION CODE. ANY FUTURE OFFER OR SALE OF THE STRATEGY AND/ OR ANY SECURITIES IS SUBJECT TO REGISTRATION REQUIREMENTS UNDER THE CODE, UNLESS SUCH OFFER OR SALE QUALIFIES AS AN EXEMPT TRANSACTION.

**Singapore**—Issued by T. Rowe Price Singapore Private Ltd. (UEN: 201021137E), 501 Orchard Rd, #10-02 Wheelock Place, Singapore 238880. T. Rowe Price Singapore Private Ltd. is licensed and regulated by the Monetary Authority of Singapore. For Institutional and Accredited Investors only.

**South Africa**—Issued in South Africa by T. Rowe Price International Ltd (TRPIL), Warwick Court, 5 Paternoster Square, London EC4M 7DX, is an authorised financial services provider under the Financial Advisory and Intermediary Services Act, 2002 (Financial Services Provider (FSP) Licence Number 31935), authorised to provide "intermediary services" to South African Investors. TRPIL's Complaint Handling Procedures are available to clients upon request. The Financial Advisory and Intermediary Services Act Ombud in South Africa deals with complaints from clients against FSPs in relation to the specific services rendered by FSPs. The contact details are noted below: Telephone: +27 12 762 5000, Web: [www.faisombud.co.za](http://www.faisombud.co.za), Email: [info@faisombud.co.za](mailto:info@faisombud.co.za)

**Switzerland**—Issued in Switzerland by T. Rowe Price (Switzerland) GmbH, Talstrasse 65, 6th Floor, 8001 Zurich, Switzerland. For Qualified Investors only.

**Taiwan**—This does not provide investment advice or recommendations. Nothing in this material shall be considered a solicitation to buy, or an offer to sell, a security, or any other product or service, to any person in the Republic of China.

**Thailand**—This material has not been and will not be filed with or approved by the Securities Exchange Commission of Thailand or any other regulatory authority in Thailand. The material is provided solely to "institutional investors" as defined under relevant Thai laws and regulations. No distribution of this material to any member of the public in Thailand is permitted. Nothing in this material shall be considered a provision of service, or a solicitation to buy, or an offer to sell, a security, or any other product or service, to any person where such provision, offer, solicitation, purchase or sale would be unlawful under relevant Thai laws and regulations.

**UK**—This material is issued and approved by T. Rowe Price International Ltd, Warwick Court, 5 Paternoster Square, London EC4M 7DX which is authorised and regulated by the UK Financial Conduct Authority. For Professional Clients only.

**USA**—Issued in the USA by T. Rowe Price Associates, Inc., 100 East Pratt Street, Baltimore, MD, 21202, which is regulated by the U.S. Securities and Exchange Commission. For Institutional Investors only.

© 2023 T. Rowe Price. All Rights Reserved. T. ROWE PRICE, INVEST WITH CONFIDENCE, and the Bighorn Sheep design are, collectively and/or apart, trademarks of T. Rowe Price Group, Inc.